Dyspepsia and epigastric pain

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Epigastric symptoms require precise language. Epigastric pain syndrome describes pain or burning centred above the umbilicus; postprandial distress features early satiation and uncomfortable fullness. Heartburn rises retrosternally, while biliary pain generally builds to a sustained severe epigastric or right upper-quadrant episode and is not simply meal-responsive indigestion. Pancreatitis produces persistent pain, often radiating to the back, with vomiting and systemic illness. Peptic ulcer disease may cause localised dyspepsia or present only when it bleeds or perforates. No timing rule reliably distinguishes benign from serious disease, so physiology and warning features come first.

Assessment should identify cancer risk and reversible causes. Record age, symptom onset and progression, dysphagia, odynophagia, weight trajectory, vomiting, bleeding, anaemia, family history and previous ulcer or gastric surgery. Ask about NSAID and aspirin exposure, including over-the-counter products, tobacco and alcohol. Examination looks for pallor, cachexia, nodes, oral signs, jaundice, abdominal mass, organomegaly and tenderness; a normal examination is common in both functional dyspepsia and early structural disease. Apply the current NICE NG12 recommendations rather than memorising an isolated age threshold because symptom combinations and pathway wording can change.

In a stable person without an urgent endoscopy indication, choose between non-invasive H pylori test-and-treat and empirical PPI treatment according to NICE and local practice. Urea breath testing or monoclonal stool antigen testing requires removal of PPI suppression for two weeks; recent antibiotics can also cause false-negative results. If symptoms persist after eradication or adequate acid suppression, confirm what was actually taken, revisit warning features and consider endoscopy or alternative imaging. A normal endoscopy with a compatible phenotype supports functional dyspepsia, which is managed through explanation, regular smaller meals, avoidance of individual triggers rather than blanket restriction, and selected pharmacological or psychological treatment.

Key points

Dyspepsia includes epigastric pain or burning, postprandial fullness and early satiation; retrosternal heartburn and regurgitation can overlap but point more towards reflux.
Ask about exertion, breathlessness, diaphoresis and cardiovascular risk because inferior cardiac ischaemia can present as epigastric discomfort, especially in older adults and people with diabetes.
Dysphagia, weight loss, anaemia, haematemesis, persistent vomiting, an upper abdominal mass and age-linked new symptoms trigger the current endoscopy or suspected-cancer pathway.
Review NSAIDs, aspirin, corticosteroid combinations, bisphosphonates, iron, potassium and medicines affecting gastric emptying before assuming primary acid disease.
For non-invasive Helicobacter pylori testing, arrange a two-week proton-pump inhibitor washout and avoid testing too soon after antibiotics, following the selected assay and local laboratory instructions.
NICE supports H pylori test-and-treat and a time-limited full-dose PPI trial for uninvestigated dyspepsia without alarm features; sequence and local access should be explicit.
Do not use symptom response to a PPI as proof of benign disease. Reassess adherence, indication, warning features and alternative biliary, pancreatic or cardiac causes when symptoms persist.
Functional dyspepsia is a positive disorder of gut-brain interaction after appropriate assessment; explain meal-related sensitivity and offer layered dietary, acid-suppressing and neuromodulatory options.
After control, step down acid suppression to the lowest effective strategy and review long-term indication rather than renewing treatment indefinitely without ownership.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Acid and mucosal disease

Helicobacter pylori, peptic ulcer, reflux and NSAID-related injury commonly cause upper abdominal burning or pain, sometimes with bleeding or anaemia.

Functional dyspepsia

Disordered gastric accommodation, visceral sensitivity and gut-brain signalling can produce early satiation, postprandial fullness or epigastric pain without explanatory structural disease.

Non-gastric pathology

Biliary, pancreatic, cardiac, vascular and malignant disease may present as epigastric discomfort and should be separated using timing, alarms and targeted tests.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Mucosal irritation
Acid, infection or medicines disrupt gastric or duodenal defences, exposing sensory pathways and sometimes causing ulceration.
2
Impaired accommodation and sensitivity
Abnormal fundic relaxation, gastric emptying or heightened visceral afferent responses make normal meals feel painfully full or cause early satiation.
3
Referred or obstructive pain
Cardiac ischaemia, pancreatic inflammation, biliary pressure or gastric outlet obstruction activates overlapping visceral segments, making symptom location alone unreliable.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Uncomplicated dyspepsia phenotype

Intermittent epigastric pain, burning, early satiation or postprandial fullness without bleeding, anaemia, weight loss, progressive vomiting, dysphagia or mass supports initial primary-care management after relevant medicine and cardiac review.

Upper gastrointestinal cancer warningRed flag

Progressive dysphagia, unexplained weight loss with upper abdominal symptoms, iron-deficiency anaemia, persistent vomiting, haematemesis or an epigastric mass moves assessment to the current urgent endoscopy or suspected-cancer pathway.

Peptic ulcer complicationRed flag

Melaena, haematemesis, syncope or anaemia suggests bleeding; sudden severe generalised pain with rigidity suggests perforation. NSAIDs, aspirin, H pylori and previous ulcer disease raise probability.

Cardiac epigastric presentationRed flag

Pressure, exertional association, breathlessness, sweating, radiation or cardiovascular risk should prompt ECG and acute coronary assessment. Reproducible meal association and antacid response cannot safely exclude myocardial ischaemia.

Functional dyspepsia

Chronic epigastric pain or meal-related fullness with no explanatory structural disease and no new warning feature supports a gut-brain interaction disorder. Symptoms remain real and may coexist with reflux or IBS.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
ECG and cardiac biomarkersFirst step
Why
Exclude acute coronary syndrome when epigastric discomfort has exertional, autonomic or cardiovascular-risk features.
Interpretation and limitations
Follow the acute chest-pain pathway; one normal ECG does not exclude evolving ischaemia. Do not postpone cardiac assessment while trialling antacid treatment.
02
Full blood count and ferritin
Why
Identify iron-deficiency anaemia or blood loss that changes endoscopy urgency and cancer probability.
Interpretation and limitations
Iron deficiency needs a gastrointestinal and other cause assessment appropriate to age and context. A normal count does not exclude ulcer or early cancer when warning symptoms persist.
03
Urea breath test or stool antigen
Why
Detect active H pylori infection non-invasively and select eradication treatment in uncomplicated dyspepsia.
Interpretation and limitations
Stop PPI for two weeks and respect the assay interval after antibiotics. Serology may remain positive after eradication and is not generally suitable for confirming cure; local testing pathways govern.
04
Liver profile and lipase
Why
Assess biliary obstruction, hepatitis or pancreatitis when pain quality, jaundice or systemic illness makes these plausible.
Interpretation and limitations
A cholestatic pattern supports biliary imaging, while appropriately elevated lipase with compatible pain supports pancreatitis. Normal tests do not explain progressive dysphagia, bleeding or weight loss.
05
Upper gastrointestinal endoscopy
Why
Identify cancer, ulcer, oesophagitis, stricture and other mucosal disease when warning features or persistent symptoms justify direct visualisation.
Interpretation and limitations
Biopsy strategy and rapid-access timing follow indication and local standards. A normal examination supports but does not by itself define functional dyspepsia; review whether biliary, pancreatic or motility questions remain.
06
Abdominal ultrasound or cross-sectional imaging
Why
Investigate gallstones, biliary dilatation, pancreatic or other structural disease when the phenotype is not luminal dyspepsia.
Interpretation and limitations
Ultrasound is first-line for gallstone questions, while CT or MR techniques answer pancreatic and ductal questions. Do not substitute endoscopy for a strong biliary hypothesis or vice versa.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Acute coronary syndrome

Exertional pressure, breathlessness, sweating, cardiovascular risk or ECG change requires cardiac assessment, especially in older adults and people with diabetes.

Ulcer or upper-GI cancer

Bleeding, iron-deficiency anaemia, weight loss, dysphagia, persistent vomiting or a mass requires prompt endoscopy rather than prolonged empirical treatment.

Biliary or pancreatic disease

Right-upper-quadrant attacks, jaundice, back radiation, persistent severe pain or abnormal liver and pancreatic tests support hepatopancreatobiliary imaging.

Additional chapter-specific clues

Biliary or pancreatic alternative

Sustained right upper-quadrant or epigastric attacks, jaundice or fever point to biliary disease, while persistent back-radiating pain with vomiting and systemic change supports pancreatitis. These require targeted blood tests and imaging, not routine dyspepsia treatment alone.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01TriageSeparate emergency and alarm diseaseFirst stepA patient presents with new or worsening epigastric pain or dyspepsia.

1Check haemodynamics and look for bleeding, peritonism, cardiac ischaemia, jaundice with sepsis and severe dehydration, sending unstable patients to acute care.
2Elicit dysphagia, weight loss, anaemia, persistent vomiting, mass, family history and age-linked onset, then apply the current NG12 and endoscopy pathway.
3Review ulcerogenic and motility-altering medicines and identify biliary, pancreatic and cardiac features before assigning uncomplicated dyspepsia.
4Document the chosen pathway, expected response and named trigger for earlier reassessment.

02Initial treatmentTest or suppress acid deliberatelyStable uninvestigated dyspepsia has no urgent endoscopy indication.

1Choose H pylori test-and-treat or a four-week full-dose PPI trial according to NICE and local sequence, explaining that each is a time-limited diagnostic-management step.
2If testing, arrange appropriate PPI and antibiotic washout, use a validated breath or stool assay and establish who will act on the result.
3Treat confirmed infection using the current local eradication regimen, then review symptom response and whether post-treatment confirmation is indicated.
4For PPI response, step down after the initial course and reassess rather than allowing indefinite repeat prescribing without diagnosis or review.

03Persistent symptomsCheck premise before escalationEscalationSymptoms continue despite an appropriate initial treatment course.

1Verify adherence, actual PPI timing, H pylori test validity, NSAID exposure and whether the dominant symptom remains dyspepsia.
2AlternativeReassess warning features and alternative cardiac, biliary, pancreatic, medication and gastroparesis clues, repeating examination and selected bloods where the phenotype changed.
3Arrange endoscopy or targeted imaging when the unresolved question justifies it, and use gastroenterology review for refractory or diagnostically discordant symptoms.
4If structural assessment is negative and the phenotype fits functional dyspepsia, explain the diagnosis and offer layered dietetic, acid-suppressing, neuromodulatory and psychological options.

04Long-term reviewMinimise treatment burden safelySymptoms are controlled on ongoing acid suppression or after eradication.

1Confirm the continuing indication, using the lowest effective dose, intermittent strategy or cessation where clinically appropriate.
2Review NSAID and gastroprotection need, adherence, adverse effects and any recurrence pattern at medication reviews.
3Investigate new dysphagia, bleeding, anaemia, vomiting or weight loss as a new presentation rather than automatically increasing PPI treatment.

Key medicines and prescribing safety2 treatments · regimens, roles and cautions

Reduces acid-related symptoms and promotes healing in relevant ulcer or reflux disease while the diagnostic pathway is completed.

Proton-pump inhibitor

Use a full-dose four-week course for uninvestigated dyspepsia under NICE, then step down to the lowest effective or intermittent approach after response review.

Arrange a two-week washout before breath or stool H pylori testing. Review interactions, long-term indication and adverse-effect burden, and do not let response defer investigation of alarm features.

Eradicates a major cause of peptic ulcer disease and may improve H pylori-associated dyspepsia.

Helicobacter pylori eradication therapy

Give the current locally recommended one-week combination regimen selected for penicillin allergy, previous antibiotic exposure and regional resistance, then support full adherence.

Check allergies, interactions and antimicrobial history. Failed therapy should not be repeated blindly; follow local rescue and confirmation guidance, and investigate alarm symptoms independently of infection status.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Bleeding, perforation or obstruction

Unrecognised ulcer or tumour may haemorrhage, perforate or block gastric emptying, converting a common symptom into an acute surgical or resuscitation emergency.

Weight loss and nutritional decline

Early satiety, pain or vomiting can reduce intake and cause dehydration, sarcopenia and deficiencies even when the disorder is non-malignant.

Delayed serious diagnosis

Repeated acid suppression without reviewing alarm features can postpone cancer, cardiac, biliary or pancreatic diagnosis and create avoidable harm.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record haemoglobin and any overt bleeding, weight trajectory, vomiting, swallowing difficulty and symptom progression at each review rather than monitoring pain alone.
Track every H pylori result to treatment or documented negative action, and confirm that pre-test PPI and antibiotic washout made the result interpretable.
Review PPI benefit after the planned course, attempt step-down where safe and record the indication when continuing long term.
Ensure urgent endoscopy referrals and histology have a named reviewer, with safety-netting if access is delayed or symptoms worsen.
For functional dyspepsia, follow early satiation, nutritional intake, weight and functional impact, escalating dietetic support if restriction develops.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Dyspepsia is a symptom family

Epigastric burning, early satiation and postprandial fullness reflect different mechanisms. Naming the dominant feature makes treatment and reconsideration more precise than calling every upper abdominal sensation reflux.

PPI response lacks specificity

Acid suppression can improve ulcer, reflux and functional symptoms through several pathways. Clinical improvement therefore supports continued management but cannot prove benignity or exclude cancer when warning features exist.

Test preparation changes truth

PPI and recent antibiotic exposure suppress H pylori and create false-negative breath or stool tests. Recording washout is part of interpretation, not merely an administrative instruction.

Eradication and cure differ

Prescribing an eradication pack does not establish microbiological success. Adherence, resistance and indication determine whether a correctly timed non-invasive confirmation test is required.

Meal symptoms can starve

Early satiation may lead to progressive food avoidance even without weight loss at presentation. Small regular meals and early dietetic review protect nutrition while organic and functional causes are addressed.

11Common pitfallsFrequent interpretation and management errors.

01
Treating exertional epigastric pressure as indigestion without an ECG or acute coronary assessment.
02
Performing an H pylori breath or stool test while the patient continues a proton-pump inhibitor.
03
Using a successful PPI trial to overrule progressive dysphagia, anaemia or weight loss.
04
Repeating eradication antibiotics without checking adherence, prior exposure and the local resistance-led rescue pathway.
05
Calling sustained right upper-quadrant attacks functional dyspepsia without biliary investigation.
06
Renewing long-term acid suppression without recording indication, benefit or a step-down review.